Cellectar Biosciences (CLRB) Reports CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma
Tweet Send to a Friend
Cellectar Biosciences, Inc. (NASDAQ: CLRB) today announced initial results from Cohort 6 in the Company’s ongoing Phase 1 clinical study ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
